sotorasib

Org: Memorial Sloan Kettering Cancer Center, Duke University Medical Center, Vall d’Hebron University Hospital/VHIO, Institut Català d'Oncologia L´Hospitalet, Ramón y Cajal University Hospital,

Abstract

Therapeutic activity of a new KRASG12C inhibitor JMKX001899 in brain metastases: Preclinical models of KRASG12C-mutant non-small cell lung cancer.

Org: CAMS Key Laboratory of Translational Research on Lung Cancer,

Abstract

Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study.

Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University Hospital Saint-Luc, Brussels, Belgium, Hospital Clinic Barcelona, Barcelona, Spain, CHU de Québec-Université Laval, Québec, QC, Canada, University of Iowa Hospitals and Clinics, Iowa City, IA,

Abstract

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

Org: The Royal Marsden Hospital and The Institute of Cancer Research,

Abstract

Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.

Org: Wakayama Medical University Hospital, Wakayama-Shi, NA, Japan, Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan, Kurume University School of Medicine, Fukuoka, Japan, Department of Respiratory and Allergy Medicine, Nagoya City University Hospital, Nagoya, Japan, Kitakyushu Municipal Medical Center, Kitakyushu, Japan,

Abstract

Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.

Org: NYP/Columbia,

Clinical trial

Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

Status: Recruiting, Estimated PCD: 2024-10-01

Abstract

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).

Org: Kumamoto University Hospital, Kurume University School of Medicine, Kitakyushu Municipal Medical Center, Wakayama Medical University, Wakayama, Japan, Internal Medicine III, Wakayama Medical University,

Abstract

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

Org: Netherlands Cancer Institute, Henry Dunant Hospital, Universitätsspital Zürich, University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre,

Abstract

Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Org: Amgen, National Cancer Center Hospital East, Kashiwa, Japan, Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,

Abstract

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

Org: University of Texas MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Duke University Medical Center, City of Hope National Medical Center, Cliniques Universitaires Saint-Luc,

Abstract

Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.

Org: Memorial Sloan Kettering Cancer Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, Perlmutter Cancer Center, New York University Langone Health,

Abstract

The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Thoraxklinik, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg,

Abstract

Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors.

Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, Georgetown - Lombardi Comprehensive Cancer Center,

Abstract

Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States.

Org: Faculty of Biology, Technion-Israel Institute of Technology, Carelon Digital Platforms,

Abstract

SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.

Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Kras Kickers, GO2 Foundation for Lung Cancer, Addario Lung Cancer Medical Institute,

Abstract

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, University Medical Center Utrecht, Sotiria General Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Centre Hospitalier Universitaire de Liège,

Abstract

Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.

Org: Qualigen Therapeutics, Dept. Medicine, Brown Cancer Center University of Louisville, Departments of Medicine and Pharmacology & Toxicology, James Graham Brown Cancer Center,

Abstract

Efficacy and safety of Kras inhibitors in pancreatic cancer: A systematic review of clinical trials.

Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, Saint michaels medical center, Saint Mary's and Saint Clare's Hospital, St. Michael's Medical Ctr,

Abstract

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.

Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, New Haven, CT, NYU Langone-Laura and Isaac Perlmutter Cancer Center, New York, NY,

Abstract

ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).

Org: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center,

Abstract

No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling.

Org: Datar Cancer Genetics Europe GmbH, Datar Cancer Genetics, Novustat GmbH,

Abstract

Molecular characteristics of KRAS mutations in Chinese patients with cancer.

Org: General Hospital of Ningxia Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,

Product

AMG 510

Product

sotorasib plus carboplatin and pemetrexed

Product

Sotorasib (SG)